Technology - cplbio.com

Nowadays the technology is progressing in rapid synergy with one another, bringing about startling advances in fields ranging from medicine to nanotechnology to computing.

CPL Biologicals Virus Like Particles (VLP) and Recombinant Nanoparticle Technology gives us significant advantage over conventional vaccines for speed of development, safety and efficacy.

Partnerships and collaborations

In order to achieve our mission of providing Novel, affordable solutions for Global healthcare, we are looking to partner with individuals, academia, and industries to advance products and technologies towards commercialization.
Please contact info@cplbio.com for more details
For partnerships in Vaccines, Biologics and Diagnostics please contact collaborate@cplbio.com

Advantages of our Manufacturing Technology

Our manufacturing platform has a number of important advantages

Our carefully designed genetic constructs allow us to tailor our vaccines to key components of pathogens, which we believe enhances functional immunity and leads to better protection against infection and disease.

Our Sf9/BV platform efficiently expresses large antigens and particles, which in turn promote superior immunogenicity and better functional immunity.

Our manufacturing platform can produce proteins that are properly folded and modified, which can be critical for functional, protective immunity.

Unlike traditional influenza vaccine manufacturing, we do not need to grow an actual influenza virus, obtain embryonated chicken eggs, adapt the virus or optimize new strains to grow in eggs. This 50-year old method requires four to six months lead time to produce a new strain of virus and significant investment in fixed production facilities.

Our Sf9/BV recombinant technology platform is the basis for a portfolio of novel vaccines that represent important advances and address current unmet medical needs. Our innovation introduces a significant immunologic advantage, embodied by the presentation of antigens as highly immunogenic particles in their native configuration, and sound principles of development, as a scalable, efficient recombinant vaccine production system.